Precision AI Improving Neurodegenerative Clinical Outcomes
Built by experts. Backed by science. Designed for trials.
Our Mission
To accelerate the development of disease-modifying therapies by providing precise diagnostic insights and patient stratification tools for neurodegenerative clinical trials.
Our Vision
To be the trusted partner for researchers and trial sponsors striving to improve diagnostic accuracy, reduce trial costs, and bring treatments to patients faster.
What is neuropacsTM?
neuropacs™ is a comprehensive suite of AI-powered, imaging-enabled software built specifically for neurodegenerative diseases to:
- Detect disease
- Quantify neurodegeneration
- Analyze clinical diagnostics
- Improve clinical trial outcomes
Measure
Quantitative progression markers for efficacy assessment
Stratify
Advanced diagnostic tools for precise patient stratification
Optimize
Precision inputs bolster clinical endpoint achievement
Comprehensive Toolset
Delivered via secure cloud-based workflow
Unmatched Accuracy
Up to 96% precision in distinguishing PD from MSAp and PSP
Whether supporting clinical decision-making or powering trial success, neuropacs™ provides exclusive methodologies, actionable insights, and a seamless integration into existing imaging workflows.
Why use neuropacsTM?
neuropacs™ isn’t just imaging, it’s a platform for precision trial success.
Quantitative Disease Insights
Measures severity, rate, and state of degeneration.
Next -Level Sensitivity
Detects subtle microstructural changes between closer timepoints, beyond what volumetric imaging sees.
Proved Efficiency
Faster recruitment, reduced screen fails, lower trial costs.
Better design = higher chance of reaching endpoints
96%
Up to 96% accuracy
21 sites
involved in most recent clinical trial
15+
Years of data collected
1000+
Unique datasets analyzed
Exclusive, Patented Technology
neuropacs™ leverages proprietary, patent-protected techniques that combine:
-
AI-driven diagnostics trained on
harmonized multi-site data - Exclusive Patent: US 10,758,170 for Parkinsonism
- Patent pending for Dementia and Alzheimer’s
- Free-Water Imaging (FWI): A powerful diffusion MRI method that enhances early disease detection
- FDA classification: DEN240071 for the first Parkinsonian syndrome diagnostic aid.
Our Patents
Patents and patent-pending filings cover multiple neurodegenerative indications, including:
•Alzheimer’s Disease
•Parkinson’s Disease
•Multiple System Atrophy (MSA)
•Progressive Supranuclear Palsy (PSP)
•Dementia with Lewy Bodies
•Amyotrophic Lateral Sclerosis (ALS)
•Motor Neuron Disease (MND)
•Corticobasal Degeneration
•Huntington’s Disease Multiple Sclerosis (MS)
Evidence and Expertise
neuropacs™ is the result of decades of research led by world-class clinicians and neuroscientists from:
•University of Florida
•UF Health Norman Fixel Institute for Neurological Diseases
Validated across thousands of MRI scans and multiple clinical trials, neuropacs™ delivers:
•Peer-reviewed results
•Academic rigor
•Real-world applicability
•FDA enabled
•Most sensitive platform available
Ready to improve your outcomes using our precision AI platform?
Our dedicated team can help you determine which neuropacs™ solution best fits your clinical or research needs.